Küçük Bekir, Kadayıfçılar Sibel, Eldem Bora
Department of Ophthalmology, Hacettepe University, Ankara 06100, Turkey.
Int J Ophthalmol. 2018 Apr 18;11(4):645-649. doi: 10.18240/ijo.2018.04.18. eCollection 2018.
To investigate the long-term visual and anatomical outcomes of patients who underwent intravitreal ranibizumab monotherapy to treat neovascular age-related macular degeneration (AMD) and followed-up for at least 2y.
A total of 74 eyes of 74 patients who underwent ranibizumab monotherapy for neovascular AMD were included in this retrospective study.
The average patient age was 72.1±6.5 (range, 57-85)y, the average follow-up time 46.2±13.1 (range, 24-75)mo, and the average number of visits 24.1±9.5 (range, 8-48). The mean number of injections in year 1 was 4.5, 1.6 in year 2, 0.9 in year 3, 0.4 on year 4, and 0.1 in the following years. Within the entire follow-up period, the mean number of injections was 7.6±4.4 (range, 2-21). The mean visual acuity was 48.1±15 (range, 15-76) letters at baseline and 45.7±19 (range, 7-75) at year 5. The mean central macular thickness was 303±78 (range, 178-552) µm at baseline and 251±51 (range, 138-359) µm at year 5. Scars developed in 47 (63.5%) eyes at the end of the follow-up period, and atrophy was evident in 6 (8.1%) eyes.
Ranibizumab monotherapy can stabilize visual acuity for a mean period of 4y in patients with neovascular AMD.
研究接受玻璃体内注射雷珠单抗单药治疗新生血管性年龄相关性黄斑变性（AMD）并随访至少2年患者的长期视力和解剖学转归。
本回顾性研究纳入了74例接受雷珠单抗单药治疗新生血管性AMD患者的74只眼。
患者平均年龄为72.1±6.5（范围57 - 85）岁，平均随访时间为46.2±13.1（范围24 - 75）个月，平均就诊次数为24.1±9.5（范围8 - 48）次。第1年平均注射次数为4.5次，第2年为1.6次，第3年为0.9次，第4年为0.4次，之后各年为0.1次。在整个随访期内，平均注射次数为7.6±4.4（范围2 - 21）次。基线时平均视力为48.1±15（范围15 - 76）个字母，第5年时为45.7±19（范围7 - 75）个字母。基线时平均中心黄斑厚度为3️⃣0️⃣3️⃣±7️⃣8️⃣（范围1️⃣7️⃣8️⃣ - 5️⃣5️⃣2️⃣）μm，第5年时为2️⃣5️⃣1️⃣±5️⃣1️⃣（范围1️⃣3️⃣8️⃣ - 3️⃣5️⃣9️⃣）μm。随访期末47只（63.5%）眼出现瘢痕，6只（8.1%）眼有明显萎缩。
雷珠单抗单药治疗可使新生血管性AMD患者的视力平均稳定4年。
